英文字典,中文字典,查询,解释,review.php


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       


安装中文字典英文字典辞典工具!

安装中文字典英文字典辞典工具!










  • HER2-Negative Breast Cancer: Meaning Treatment
    HER2-negative breast cancer involves having cancerous cells in your breast that don’t contain high levels of the protein human epidermal growth factor 2 (HER2) With most breast cancers, hormones and or the HER2 protein fuel cancer growth For example, with HER2-positive breast cancer, excess HER2 leads to cancerous tumors
  • Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative . . .
    Here, the author report the efficacy and safety of afuresertib, a pan AKT inhibitor, plus fulvestrant (hormone therapy) in patients with pretreated, HR-positive, HER2- negative advance breast cancer
  • VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without . . .
    For most treatment-naïve patients with hormone receptor–positive, human epidermal growth factor 2 (HER2)–negative advanced breast cancer (ABC), combination therapy with an endocrine agent and a cyclin-dependent kinase 4 6 inhibitor (CDK4 6i) is recommended 1 - 3 The majority of patients, however, eventually develop resistant disease, and
  • Updates to the Management of HR-Positive, HER2-Negative Breast Cancer . . .
    Metastatic hormone receptor–positive, HER2-negative breast cancer treatment is increasingly individualized as more of the tumor landscape is described and targeted therapies are developed CDK4 6 inhibitors have demonstrated consistency in prolonging progression-free survival across several clinical trials in advanced disease Research in endocrine therapy highlighted the noninferiority of
  • Novel Drug Combination Shows Promise for Advanced HER2-Negative Breast . . .
    A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center The treatment included a histone deacetylase (HDAC) inhibitor — a drug that causes a
  • Treatment for hormone receptor-positive, HER2-negative advanced breast . . .
    ET alone or in combination with targeted for metastatic hormone receptor-positive, HER2-negative breast cancer is presented here The treatment of HER2-positive disease is discussed elsewhere, as is chemotherapy for ET-resistant, metastatic hormone receptor-positive breast cancer
  • Identifying immune-related predictive factors for post . . . - PubMed
    Background: In the EMBRACE study, eribulin (ERI) monotherapy improved the overall survival (OS) of patients with HER2-negative advanced breast cancer (HER2-negative ABC) A post hoc analysis identified the baseline absolute lymphocyte count (ALC) as a predictive marker in the ERI arm; nevertheless, factors affecting post-ERI had not been well explored Patients and methods: We retrospectively
  • FDA Grants Priority Review to Gedatolisib for HR+, HER2-Negative . . .
    FDA grants priority review for gedatolisib, a promising treatment for advanced HR+ HER2– breast cancer, showcasing significant efficacy in recent trials


















中文字典-英文字典  2005-2009